Presentaci

1
SCIENTIFIC RESEARCH PRODUCT DEVELOPMENT
Facts Figures
10 Major Institutions

• 5 500 Workers
• 1 100 Researchers
• 100 Projects
• 60 New Products in Development
• 500 Patents

2

• MENINGITIS B VACCINE
• REC HEPATITIS B VACCINE
• LEPTOSPIRA VACCINE
• SALMONELLA VACCINE
• REC STREPTOKINASE
• COLONY STIMULATING FACTOR
• MONOCLONAL ANTIBODY hR3 (CANCER)
• MONOCLONAL ANTIBODY anti-CD3 (TRANSPLANT)
• NATURAL AND REC INTERFERONS
• REC EPIDERMAL GROWTH FACTOR
• POLICOSANOL
• SUMA SYSTEM (NATIONAL AND INTERNATIONAL NETWORK)
• NEURONIC SYSTEM (NATIONAL AND INTERNATIONAL
  NETWORK)

PRODUCTS APPROUVED
THE PIPELINE

• COMBINED VACCINES
• AIDS VACCINE
• CHOLERA VACCINE
• CANCER VACCINES (4)
• INTERLEUKIN-2
• MABS FOR CANCER TREATMENT
• MABS FOR AUTOIMMUNE DISEASES
• NEW RADIOACTIVE MABS
• NEW INTERFERON FORMULATIONS

PRODUCTS IN CLINICAL TRIALS

• HEPATITIS C VACCINE
• DENGUE VACCINE
• LPS BINDING PEPTIDES
• NEW CANCER VACCINES
• HIV INHIBITORS
• NEW DIAGNOSTIC SYSTEMS
• NEW NEUROSCIENCE EQUIPMENT

RESEARCH PROJECTS
3
PRODUCT PIPELINE FEATURES
BALANCE ADVANCED STAGE EARLY STAGE.
BALANCE LOW RISK HIGH RISK.
HEALTH NEED DRIVEN. HEALTH NEED DRIVEN.
BIASED TO VACCINES. BIASED TO VACCINES.
CLOSED LOOP DESIGN. CLOSED LOOP DESIGN.
4
MAIN RESEARCH FOCUS

• Therapeutic Vaccines and New Adjuvants
• Proteomics
• Populational Genetics
• Bioinformatics
• Transgenic Plant Products
• Neurosciences
• New Formulations

5
Center for Molecular Immunology
6
THREE COMPONENTS IN THE CANCER PROGRAM
7
Product Molecule Obtention Pre-Clinical Evaluation Early Clinical Trial Advanced Clinical Trial Process Develop. Launched
1. Citostatics
2. Rec IFN?
3. Leucocyte IFN?
4. Anti-CEA-Tc99 MAB
5. Anti-EGF-R-Tc99 MAB
6. Anti-Colon-Tc99 MAB
7. Eritropoetin
8. G-CSF
9. Anti-EGF-R MAB
10. Rec IL-2
11. EGF Vaccine
12. Gangliosides Vaccine
13. Idiotypic Vaccine
14. Re-188 MABs
15. Anti-CD6 MAB
16. ScFv (RAID/RAIT)
17. Microbial Antitumor Agent
18. HER-1/TGF? Vaccines
19. GNRH Vaccine
20. VEGF Vaccine
21. HPV Vaccine
22. Recombinant MABs
THE CANCER PIPELINE
8
Sequential images with 99mTc-ior C5. High uptake
in the colorectal tumor of the ascending colon is
shown 3 hours after injection. Clearance of blood
pool is observed at 24 hours.
10 minutes
1 hour
3 hours
24 hours
9
COMPLETE REMISSION ADVANCED HEAD NECK CANCER
PATIENTS
Tumor (Base Tongue)
Complete Remission
10
HN OVERALL RESPONSE RATE TO TREATMENTS
Regimen of Treatment Overall Response ()
Radiotherapy 30-40
Radiotherapy Chemotherapy 50-60
Radiotherapy EGF-R TheraCIM h-R3 70-90
11
THE EGF VACCINE SURVIVAL OF THE PATIENTS WITH
HIGH AND LOW TITER VERSUS EGF
12
PATIENT 2.5 TUMOR REGRESSION ON MONTH 12
Before treatment
After treatment
13
NGCGM3/VSSP VACCINE. MELANOMA
14
ANTIMETASTATIC EFFECT OF 1E10 MAB IV TREATMENT IN
3LL-D122 TUMOR MODEL